Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

Published Date: 02 Apr 2026

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Read Full News

Latest News

Despite Medicare Coverage, Cancer Genomic Testing Still Low

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Transperineal Biopsy IDs Active Surveillance Candidates

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Todays Updates

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Latest News

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

News All Time

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

Gedatolisib Combo Approved for Advanced Breast Cancer

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

MGRS Relapse-Free Survival Better With Maintenance Therapy

Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.

Race, Geography Linked to Gaps in Prostate Cancer Care

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

Breast Cancer Incidence Rises in Asian American Women

A cross-sectional population-based study examines trends in invasive breast cancer incidence rates in Asian American, Native Hawaiian, and Pacific Islander ethnic groups.

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Recommended News For You

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

What Role Should Genomic Classifier Testing Play in Prostate Cancer?

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

Recommended Articles For You

Uncovering the Secrets of CA19-9: A Blood Test for Cancer Diagnosis 

AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data 

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer 

Emerging Insights in Hematology for Better Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Daily physical activity, even at light intensities, linked to lower cancer risk

2.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

3.

Citing a cancer risk, the EPA sets a new limit on medical sterilization chemicals.

4.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

5.

Common intracellular toxin could help fight leukemia

1.

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined

2.

Epigenetic Signatures for Multi-Cancer Screening

3.

Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia

4.

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control

5.

Revolutionizing Cancer Treatment: ESMO's Updated Recommendations for Tumour NGS

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective

2.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

3.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

5.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot